Our results indicate an inhibitory role for STAT3 in CD103+ cDC1-mediated anti-tumor immunity, including STAT3-dependent suppression of cDC1 maturation and IFN-γ+ T cell responses. The gene discussed is STAT3; the disease is neoplasm.